Valuation: Relay Therapeutics, Inc.

Market Cap 4.13B 3.71B 3.42B 3.1B 5.8B 392B 5.87B 41.02B 16.29B 206B 15.5B 15.17B 652B P/E 2026 *
-11.7x
P/E 2027 * -11.7x
Enterprise Value 3.56B 3.19B 2.95B 2.67B 5B 338B 5.06B 35.35B 14.04B 177B 13.36B 13.07B 562B EV / Sales 2026 *
318x
EV / Sales 2027 * 206x
Free-Float
91.42%
Yield 2026 *
-
Yield 2027 * -
1 day+3.97%
1 week+2.11%
Current month+4.38%
1 month+7.84%
3 months+1.07%
6 months+26.02%
Current year+122.70%
1 week 17.68
Extreme 17.68
18.96
1 month 16.13
Extreme 16.13
19.5
Current year 7.01
Extreme 7.01
21.27
1 year 5.95
Extreme 5.95
21.27
3 years 1.78
Extreme 1.775
21.27
5 years 1.78
Extreme 1.775
37.52
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 01/03/2017
Director of Finance/CFO 49 01/04/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 04/05/2015
Director/Board Member 66 01/07/2016
Director/Board Member 52 01/03/2017
Date Insider Type Main position Quantity % Market Cap. Importance
7/10/26 Sell

Chief Executive Officer

-48,199 0.0220%
6/10/26 Sell

Chief Financial Officer

-17,717 0.0081%
8/9/26 Sell

Chief Financial Officer

-17,717 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
+3.97%+2.11%+155.28%+210.89% 4.13B
-3.10%-4.19%+32.67%+59.47% 63.48B
+0.33%+0.33%+10.16%+78.07% 54.55B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 44.75B
-1.30%-4.80%+16.05%+114.76% 41.62B
+1.26%-5.26%+221.12%+900.64% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+1.11%+15.18%+60.27%+49.33% 26.7B
+3.85%-6.07%+26.22%-8.12% 23.36B
Average +0.48%-0.86%+56.76%+160.27% 38.46B
Weighted average by Cap. -0.25%-1.24%+44.17%+155.91%

Financials

2026 *2027 *
Net sales 11.19M 10.04M 9.27M 8.41M 15.71M 1.06B 15.9M 111M 44.14M 557M 41.99M 41.09M 1.77B 17.91M 16.08M 14.84M 13.46M 25.16M 1.7B 25.47M 178M 70.68M 892M 67.24M 65.8M 2.83B
Net income -320M -287M -265M -241M -450M -30.41B -455M -3.18B -1.26B -15.94B -1.2B -1.18B -50.54B -347M -312M -288M -261M -488M -32.99B -494M -3.45B -1.37B -17.29B -1.3B -1.28B -54.84B
Net Debt -571M -512M -473M -429M -802M -54.21B -811M -5.67B -2.25B -28.41B -2.14B -2.1B -90.1B -442M -397M -366M -332M -621M -41.98B -628M -4.39B -1.74B -22.01B -1.66B -1.62B -69.78B
Projected Income Statement - Annual - Relay Therapeutics, Inc.
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
202
Date Price Change Volume
27/10/26 USD 18.84 +3.97% 2,258,311
26/10/26 USD 18.12 -0.33% 1,585,748
23/10/26 USD 18.18 -0.87% 1,898,940
22/10/26 USD 18.34 -0.38% 1,721,973
21/10/26 USD 18.41 -0.22% 1,598,194
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Relay Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
18.84USD
Average target price
27.58USD
Spread / Average Target
+46.41%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Relay Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RLAY Stock